Soligenix Inc. (NASDAQ: SNGX), a biopharmaceutical company specializing in rare diseases, has announced successful outcomes from its Phase 2a proof of concept study for SGX945 (dusquetide) in treating Behçet’s Disease. The study met its primary objective by demonstrating a 40% improvement in the ulcer endpoint compared to a historical placebo group from the apremilast (Otezla(R)) Phase 3 study. Notably, these results were achieved with treatment cessation at four weeks, matching or surpassing outcomes seen with apremilast.
Among the eight patients participating in the open-label trial, seven reported reductions in ulcer duration, number, and pain, with these benefits enduring throughout the follow-up period. Importantly, no treatment-related adverse events were reported, underscoring the potential safety profile of SGX945. Christopher J. Schaber, CEO of Soligenix, highlighted the significance of these findings, stating they bolster the case for advancing SGX945, including its reformulation for home-based subcutaneous administration, as part of a broader initiative to tackle unmet needs in Behçet’s Disease and other inflammatory conditions linked to innate immune responses.
This development is particularly noteworthy for patients suffering from Behçet’s Disease, a rare, chronic condition characterized by inflammation of blood vessels throughout the body, leading to painful symptoms and significant quality-of-life impacts. The positive results from the Phase 2a study suggest that SGX945 could offer a new, effective treatment option for this underserved patient population. For more detailed information on the study and its outcomes, visit https://ibn.fm/FqcXf.
Soligenix’s commitment to addressing rare diseases with high unmet medical needs is further exemplified by its diverse pipeline, which includes potential treatments for cutaneous T-cell lymphoma, psoriasis, and vaccines for ricin toxin, filoviruses, and COVID-19. The company’s innovative approach, particularly its use of the ThermoVax(R) heat stabilization platform technology, positions it as a leader in the development of novel therapeutics and vaccines. For additional insights into Soligenix’s research and development efforts, visit https://www.Soligenix.com.
